- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Sep 21, 2017
P2, N=6, Active, not recruiting, Recruiting --> Completed Recruiting --> Active, not recruiting | N=26 --> 6 | Trial primary completion date: Apr 2019 --> Mar 2017
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 18, 2017 P2, N=56, Active, not recruiting, N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Sep 2017; Poor Accrual Trial primary completion date: Sep 2017 --> Dec 2017
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Sep 13, 2017 P1, N=32, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> May 2017 Trial primary completion date: Oct 2017 --> Feb 2018
- |||||||||| sapitinib (AZD8931) / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Sep 11, 2017 P2, N=24, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 24
- |||||||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Enrollment closed, Metastases: INVICTAN (clinicaltrials.gov) - Sep 6, 2017 P3, N=120, Active, not recruiting, Trial primary completion date: Aug 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 5, 2017 P1b/2, N=68, Suspended, Recruiting --> Active, not recruiting Recruiting --> Suspended
- |||||||||| Biomarker, Enrollment change, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 1, 2017
P2, N=1400, Recruiting, N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment. N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020
- |||||||||| palupiprant (AN0025) / Eisai, Adlai Nortye
Enrollment open, Trial primary completion date, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - Aug 15, 2017 P1b, N=68, Recruiting, Trial primary completion date: May 2017 --> Mar 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2019 --> Apr 2018
|